- Home
- BDL vs BTAI Comparison
BDL vs BTAI Comparison
Compare BDL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDL | BTAI |
|---|---|---|
| Founded | 1959 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 43.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BDL | BTAI |
|---|---|---|
| Price | $33.50 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 2.6K | ★ 658.1K |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | ★ 49.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $206,084,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $265.60 |
| P/E Ratio | $12.37 | ★ N/A |
| Revenue Growth | ★ 9.56 | N/A |
| 52 Week Low | $22.61 | $1.17 |
| 52 Week High | $35.98 | $8.08 |
Technical Indicators
Market Signals| Indicator | BDL | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 47.68 |
| Support Level | $31.20 | $1.76 |
| Resistance Level | $32.62 | $2.08 |
| Average True Range (ATR) | 1.41 | 0.14 |
| MACD | 0.26 | -0.00 |
| Stochastic Oscillator | 100.00 | 33.33 |
Price Performance
Historical ComparisonAbout BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.